Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Inclusion Criteria: * ≥ 16 years of age at the time of obtaining informed consent * Eastern Cooperative Oncology Group performance status of 0 or 1 at screening * At least one positron emission tomography (PET)-avid measurable lesion according to Modified Lugano Criteria after the last line of therapy. * Confirmed histological diagnosis of active relapse/refractory cHL * Failed at least 2 prior lines of systemic therapy. * No previous treatment with anti-TIM-3. * Adequate organ and bone marrow function * Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception * Minimum body weight ≥ 40 kg for all participants. Exclusion Criteria: * Unresolved toxicities of ≥ Grade 2 from prior therapy * Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy * Patients with central nervous system (CNS) involvement or leptomeningeal disease. * History of allogeneic stem cell transplant or organ transplantation. * Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention. * Active infection including Tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection * History of arrhythmia which is requires treatment, symptomatic or uncontrol led atrial fibrillation despite treatment, or asymptomatic sustain…